{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122815","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.928585+00:00","generated_at":"2026-05-30T03:49:07.825900+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025","bullets":["Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.","Cash and equivalents of $138.9M as of Sept 30, 2024, funding operations into 2026.","R&D expense $17.7M (down 14% YoY); G&A $5.4M (up 29% YoY).","FREEDOM-DM1 5 & 10 mg/kg data expected Q1 2025; 15 mg/kg cohort in H2 2025.","Appointed Paul Streck, MD, MBA, as EVP and Head of R&D in August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122815","json":"https://secwatch.observer/filing/0000950170-24-122815.json","markdown":"https://secwatch.observer/filing/0000950170-24-122815.md","text":"https://secwatch.observer/filing/0000950170-24-122815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/0000950170-24-122815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/pepg-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:49:07.825900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}